MPs have criticised the government’s slow response to last year’s WannaCry attack on the NHS, and warn there is much work to be done to improve cyber security if damage from the next attack is to be minimised.
Rigel Pharmaceuticals has bagged its first FDA approval, with a green light to market Tavalisse for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have failed to respond to previous treatment.
Amgen and Novartis’ closely watched experimental migraine therapy Aimovig has impressed again in late stage trials, this time hitting targets in patients for which other preventative treatments failed to work or weren’t tolerated.
MSD has unveiled further data from a trial showing that a combination of Keytruda and chemotherapy significantly improved overall survival in patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
MSD and the European Organisation for Research and Treatment of Cancer (EORTC) have released new data showing that the anti-PD-1 therapy Keytruda significantly prolonged recurrence-free survival (RFS) in patients with high-risk stage III melanoma.
The Health and Social Care Committee has voiced “serious concerns” about NHS Digital’s ability to protect patient data, after reviewing its Memorandum of Understanding with the Home Office that allows data sharing to trace immigration offenders.